Research

IN BRIEF: SINOPHARM (1099 HK)

In July, we wrote a report on Sinopharm which alleged that the company was manufacturing operating cash flow by imaginatively reclassifying creditor repayments as a financing activity (an accounting first) and by selling an ever-greater quantity of receivables. Adjust for this and there are no operating cash inflows while leverage is worryingly high. Well, no amount of window dressing could disguise the substantial operating outflows in 1H17, leading to an alarming rise in leverage (see chart below). Curiously, this occurred at a time when growth was slowing (and disappointing), not accelerating. This suggests a substantial deterioration in terms of trade,…
Read more ›

Log In

Insights

IN BRIEF: CTRIP (CTRP US)

Cashflow confusion questions premium rating

Mark Webb · 7 December 2017

Online travel agency Ctrip has delivered remarkable revenue growth. Moreover, despite the cost of integrating new businesses, Ctrip’s free cash flow also appears to have improved, with rising reported operating cashflow and falling capex. However, rather than indicating robust health, Ctrip’s headline performance shows how easily investors can be misled by the cashflow statement. The cashflow is primarily designed to assess liquidity and omits payments made using debt and equity rather than cash. In the case of Ctrip, if we include significant outflows from share-based staff pay and share-funded acquisitions in 2014-16, performance deteriorates from a headline free cash inflow…
Read more ›

IN-BRIEF: CHINA HONGQIAO (1378 HK)

Unresolved Issues (SELL/AVOID/SHORT)

Nigel Stevenson · 29 November 2017

China Hongqiao’s post-suspension share price appreciation might lead some to believe that fraud allegations have been addressed, but we are not entirely convinced. Even if investors can accept that the company had four different auditors in two years, they still have to grapple with a less than satisfactory response to fraud allegations and a very worrying set of financial statements containing similar traits to past frauds. The stock might be trading on 5x 2018 PER (assuming profits are real) but we would still be sellers. The cost of shorting is expensive at 9% but might be a strategy for risk…
Read more ›

COMING UP SHORT

Manipulating cash flows

Mark Webb · 22 November 2017

Investors increasingly view the income statement as unreliable; instead modelling cash flows to gauge performance. But the cash flow statement is flawed from an investment perspective as it only aims to reconcile movements in cash. This means that purchases funded with debt or equity are excluded which can materially distort operating and free cash flows. In this report, we discuss the most common practices affecting cash flows and highlight those stocks most impacted, such as China Southern, JD.com, Ctrip.com, China Resources Pharma and CKH Holdings. GET PDF VIEW SLIDES Payments using debt Items paid directly with debt, rather than cash,…
Read more ›

Free Newsletter

GET OUR FREE NEWSLETTER

Input your email address below to sign-up to our free newsletter.